FDA clears way for U.S. trials of Alcobra ADHD therapy


Alcobra (ADHD) will be able to start U.S. trials of its Metadoxine Extended Release (MDX) treatment for Attention Deficit Hyperactivity Disorder (ADHD), Fragile X Syndrome and other cognitive dysfunctions after the FDA approved the company's Investigational New Drug (IND) application for the treatment.

Alcobra expects to soon start enrolling adult patients in a Phase III trial of MDX. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs